The table below shows Aclaris Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$18.15M
-$13.06M
-$20.82M
-$26.35M
-$20.97M
-$12.23M
Capital expenditure
$13.00K
$43.00K
$135.00K
$553.00K
$164.00K
-
Investing cash flow
-$30.93M
$19.12M
$16.83M
$25.80M
$29.93M
-$75.31M
Dividends paid
-
-
-
-
ACRS operating cash flow (10-K history)
Aclaris Therapeutics, Inc. reported operating cash flow of -$47.11M for fiscal year 2025. That is down 134.7% from -$20.07M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$34.60M (FY 2016) to -$47.11M. Figures come from the company's audited annual reports as filed with the SEC.